药明巨诺(开曼)(02126)于2025年12月3日发布截至2025年11月30日的股份变动月报表。根据公告，普通股本月底维持416,473,250股，较上月底并无新增发行或股份回购，注册股本维持在5,000,000,000股（面值0.00001美元），对应注册股本总额50,000美元。
公司披露其已采纳的首次公开发售前后激励计划继续有效，当月无任何期权行使或失效，潜在可发行或转让股份数量保持不变。报告同时显示，截至2025年11月30日，公司并未进行购回或注销活动。
公司确认已遵守香港联交所《上市规则》及其他相关法律规定，并由公司主席及执行董事刘敏签署。公司股本在本报告期内整体保持稳定，无任何增减变动。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.